Search

Your search keyword '"Bruggmann, Philip"' showing total 378 results

Search Constraints

Start Over You searched for: Author "Bruggmann, Philip" Remove constraint Author: "Bruggmann, Philip"
378 results on '"Bruggmann, Philip"'

Search Results

1. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

2. Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs

4. Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden

5. Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral

6. Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection

9. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

10. Interdisciplinary care for users of anabolic agents in recreational sports in Switzerland – a first clinic has opened in Zurich

11. Late presentation for hepatitis C treatment: prevalence and risk factors in the Swiss Hepatitis C Cohort

12. Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohort

13. Prolonged diacetylmorphine take‐home during the COVID‐19 pandemic—Results of a retrospective cohort study.

14. Electronic Nicotine-Delivery Systems for Smoking Cessation

18. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

19. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study

21. Joint statement in support of hepatitis C human challenge studies

22. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

23. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

24. Response to "Reply to 'Assessing the hepatitis C epidemiology in Switzerland: It's not that trivial'".

29. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study

30. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

32. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

33. Incidence of sexually transmitted infections and association with behavioural factors: Time‐to‐event analysis of a large pre‐exposure prophylaxis (PrEP) cohort.

35. Securing wider EU commitment to the elimination of hepatitis C virus

36. The current and future burden of hepatitis B in Switzerland: a modelling study

37. Evidence of use and users of image- and performance-enhancing drugs in sports in Switzerland: a scoping literature review and implications for Swiss drug policy

39. Mortality and morbidity related to hepatitis C virus infection in hospitalized adults-A propensity score matched analysis

40. Hepatitis C antibody test frequencies and positive rates in Switzerland from 2007 to 2017: a retrospective longitudinal study

42. Joint statement in support of hepatitis C human challenge studies

43. Mortality and morbidity related to hepatitis C virus infection in hospitalized adults—A propensity score matched analysis.

44. Patient reported outcomes during and following HCV direct-acting antiviral treatment among people who inject drugs

46. Securing wider EU commitment to the elimination of hepatitis C virus

Catalog

Books, media, physical & digital resources